E-LIB Suche - Ergebnisse für: Munugalavadla, Veerendra

1

Mutational profile of previously treated chronic lymphocyti..:

Woyach, Jennifer A. ; Jones, Daniel ; Jurczak, Wojciech...
Blood Journal. , 2024

Link: https://doi.org/10.1182/..

2

Acalabrutinib plus venetoclax and rituximab in treatment-na..:

Wang, Michael L ; Robak Prof., Tadeusz ; Maddocks, Kami J...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

3

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) i..:

Roschewski, Mark ; Patel, Manish R. ; Reagan, Patrick M....
Clinical Cancer Research. 29 (2023) 17 - p. 3301-3312 , 2023

Link: https://doi.org/10.1158/..

4

Idelalisib reduces regulatory T cells and activates T helpe..:

Gadi, Deepti ; Griffith, Alec ; Wang, Zixu...
British Journal of Haematology. 197 (2022) 2 - p. 207-211 , 2022

Link: https://doi.org/10.1111/..

5

Bioavailability of acalabrutinib suspension delivered via n..:

Sharma, Shringi ; Pepin, Xavier ; Cheung, Jean...
British Journal of Clinical Pharmacology. 88 (2022) 10 - p. 4573-4584 , 2022

Link: https://doi.org/10.1111/..

6

Bioequivalence and Relative Bioavailability Studies to Asse..:

Sharma, Shringi ; Pepin, Xavier ; Burri, Harini...
Clinical Pharmacology in Drug Development. 11 (2022) 11 - p. 1294-1307 , 2022

Link: https://doi.org/10.1002/..

7

The highly selective Bruton tyrosine kinase inhibitor acala..:

Pinney, Jonathan J. ; Blick-Nitko, Sara K. ; Baran, Andrea M....
Haematologica. 107 (2022) 6 - p. 1460-1465 , 2022

Link: https://doi.org/10.3324/..

8

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Leukemia. 36 (2022) 4 - p. 1171-1175 , 2022

Link: https://doi.org/10.1038/..

9

Preparation of Peripheral Blood Mononuclear Cell Pellets an..

JoVE : Medicine

Marco-Casanova, Paola ; Lukashchuk, Natalia ; Lombardi, Benedetta... , 2021

Link: https://www.jove.com/t/6..

10

CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chl..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S318-S319 , 2021

Link: https://doi.org/10.1016/..

11

Safety and Efficacy of Pembrolizumab in Combination with Ac..:

Taylor, Matthew H. ; Betts, Courtney B. ; Maloney, Lauren...
Clinical Cancer Research. 28 (2021) 5 - p. 903-914 , 2021

Link: https://doi.org/10.1158/..

12

Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzum..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S220 , 2021

Link: https://doi.org/10.1016/..

13

Acalabrutinib with or without obinutuzumab versus chlorambu..:

Sharman, Jeff P ; Egyed, Miklos ; Jurczak, Wojciech...
The Lancet. 395 (2020) 10232 - p. 1278-1291 , 2020

Link: https://doi.org/10.1016/..

14

A randomized phase 2 trial of pembrolizumab versus pembroli..:

Zhang, Tian ; Harrison, Michael R. ; O'Donnell, Peter H....
Cancer. 126 (2020) 20 - p. 4485-4497 , 2020

Link: https://doi.org/10.1002/..

15

Risk factors for grade 3/4 transaminase elevation in patien..:

Brown, Jennifer R. ; Zelenetz, Andrew ; Furman, Richard...
Leukemia. 34 (2020) 12 - p. 3404-3407 , 2020

Link: https://doi.org/10.1038/..